Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism IL1RAP inhibitors(Interleukin-1 receptor accessory protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |








| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United States | 24 Dec 2021 | |
| Autoimmune Diseases | Preclinical | Sweden | 24 Dec 2021 | |
| Autoimmune Diseases | Preclinical | Sweden | 24 Dec 2021 | |
| Inflammation | Preclinical | United States | 24 Dec 2021 | |
| Inflammation | Preclinical | Sweden | 24 Dec 2021 | |
| Inflammation | Preclinical | Sweden | 24 Dec 2021 | |
| Neoplasms | Preclinical | United States | 24 Dec 2021 | |
| Neoplasms | Preclinical | Sweden | 24 Dec 2021 | |
| Neoplasms | Preclinical | Sweden | 24 Dec 2021 |






